Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study - Wikidata - awgldk - TriplyDB

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

http://www.wikidata.org/entity/Q58874870

about

European guidance for the diagnosis and management of osteoporosis in postmenopausal women An overview on the treatment of postmenopausal osteoporosis Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates.Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.Bisphosphonates for the treatment of osteoporosis: insights for clinicians.Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.Emerging pharmacologic therapies for osteoporosis.Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.Renal safety of intravenous bisphosphonates in the treatment of osteoporosis.Quarterly intravenous ibandronate for postmenopausal osteoporosis.Use of bisphosphonates in the management of postmenopausal osteoporosis.Safety of long-term bisphosphonate therapy for the management of osteoporosis.Current options for the management of postmenopausal osteoporosis.Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options.Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group.Osteoporosis treatment: why ibandronic acid?Renal safety in patients treated with bisphosphonates for osteoporosis: a review.The association between critical illness and changes in bone turnover in adults: a systematic review.Considerations regarding adherence of anti-osteoporosis therapy.Treatment of osteoporosis in renal insufficiency.The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.Ibandronate: A Review in Japanese Patients with Osteoporosis.Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.Zoledronic acid reduces osteoporotic fractures and ensures medication compliance for 1 year.Ibandronate and nonvertebral fracture efficacy: results of a recent pooled analysis.Injectable bisphosphonates for the treatment of osteoporosis.Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.Osteoporosis: non-hormonal treatment.Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology.Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness.Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.

P2860

Q24612411-35D2F650-B4C2-4B66-8100-FC001F3F83B5 Q27013070-D0EDE51F-320D-409F-8932-D768A2B0D1E3 Q33482516-87AAC94E-51E0-45FA-8261-28DE3652AAF9 Q34041189-F423508D-5544-4DDD-9A1A-169CEBD4E12F Q34189582-2EF9DAC9-DC3B-4132-9FDF-694177F23389 Q34645740-33D98CA8-C49B-455F-B1CD-F9A6A53A9B35 Q35644131-587C7582-D5C4-4AFD-A511-EC55AFF5B321 Q35940958-E983B685-7343-4FF4-9768-A4FFC9F7F0A8 Q36056975-9F674B5D-85C1-4F0B-A2FC-46A7BE99C1C3 Q36162247-2F2B2075-2A2A-49BE-B3B6-27D11725CB38 Q36443681-435D4887-A7BE-4D2D-97CB-BB1DF9730C24 Q36792733-58A250CB-CD38-4B3A-B560-D7A4D0464C42 Q36944034-109E56ED-F61E-4640-92F6-75306CA584BD Q36979311-C436B8CE-0437-4D68-AD54-F7E8A9CE3DA2 Q36984235-CE4A1B25-B2D4-4233-AD5B-1EEA4E7C15B2 Q37346101-4D0B64DD-D233-4C25-ACFB-ABD7210A675B Q37800181-9B58CEC1-F670-4433-857B-53EA77D30C6D Q37866764-76A04E10-B914-4B0F-920E-5C22991ED3F5 Q37931985-64435931-F856-4419-A84A-D56F23933350 Q37951107-9818F523-5CFA-40AF-B11C-4FB9AD555B6B Q38034435-F83F2461-2528-4535-928B-178721F80BD3 Q38104738-08190F48-7A4A-4119-B49B-33246E93CA4C Q38125952-81E66219-FF64-4B4F-98D1-519A2A466E4E Q38209896-74340D31-2225-4993-9BF7-FB1BF05583E1 Q38294766-E6F0928F-B345-4EBA-B249-B6C3C04FD287 Q38335645-4774E5D1-174C-417D-9135-B49BFC52E656 Q38611601-4579E83F-5850-4FF4-B063-CECAA7B5F111 Q38750001-8BE98D08-2F0D-4B26-A943-4F0F000B6FC4 Q41091281-F93BC8EC-F7B7-43AD-87AF-F70F5093D53A Q42171414-72BD22FB-9EA9-4F85-AE2E-E20425C55821 Q42970094-FF519DEA-B45B-4330-8CA6-94BBC83F46D3 Q43267037-6BD00E7C-36DF-4593-A45C-F7B830B6C1E7 Q44468289-1CBC1B05-F155-473A-A5C5-F801919B6576 Q44892769-251FCEC3-8E12-4E03-9B2E-7AC284DC4DC0 Q46990986-26AEECD5-96E4-4007-B78F-2334A0EC8CF9 Q47117629-F22FBF92-1AA4-43D3-9ABB-9C0D9AD8E718 Q47417160-93CB3440-058F-4366-B621-6581037493B0 Q51153117-5D0E22B5-620E-4C1B-A38D-C84183F6467B Q51487384-D4E2EA70-DFA9-4FA1-A0B7-D84758661078 Q53559191-826CB107-3121-4250-9D8B-FABDEDAE5007

P2860

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

http://www.wikidata.org/entity/Q58874870

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2006

@uk

name

Intravenous ibandronate inject ...... travenous administration study

@en

Intravenous ibandronate inject ...... travenous administration study

@nl

type

label

Intravenous ibandronate inject ...... travenous administration study

@en

Intravenous ibandronate inject ...... travenous administration study

@nl

prefLabel

Intravenous ibandronate inject ...... travenous administration study

@en

Intravenous ibandronate inject ...... travenous administration study

@nl

P1433

Q58874870-AE53ED55-A397-42E6-8C4C-2FD612B9F373

P1476

Q58874870-7A3AAE96-9881-4B7C-B51F-97B269A3D9F3

P2093

Q58874870-10A13BDD-2A61-4AFE-A9E3-3941B9A7521E

Q58874870-121774DA-5206-47EA-BD0D-63A06C417D7C

Q58874870-17926E83-A8F8-45F2-AF33-EA4B40C733D3

Q58874870-2D6B1535-35FF-4FA0-8053-010403D2EF0D

Q58874870-2DBDE1FD-583A-44B4-9448-2688C57CEB61

Q58874870-47409D5C-1D8C-4B52-A721-6C6AE589F0A6

Q58874870-6D628A9C-8442-43A2-B5B9-23592EE4125C

Q58874870-71C0238C-A1A1-4AE0-A223-863B9F3C1112

Q58874870-7EDB3A09-820B-416A-9CCA-C27AA7B3E2A7

Q58874870-93C25508-C363-4962-8AF1-B41F1DCBDD8D

P304

Q58874870-91C0EEA3-FE59-4C17-B831-9568CCE856B3

P31

Q58874870-EB94068E-B295-4575-9AED-A2DFF9572B78

P356

Q58874870-F84F6E50-5B45-42C1-864D-3A56DB46CFDF

P433

Q58874870-906F31E2-B236-4266-90DF-E0183B508207

P478

Q58874870-49E8F352-23F8-4E7F-BF51-86F8C4A43836

P50

Q58874870-656B0E94-64F7-4E9A-9DF8-159AFFD8C1E0

Q58874870-B1EC1974-DDBB-4EF5-B293-F20ECA726A78

P577

Q58874870-87428A70-1B77-47E3-8B07-F3E425CFF09F

P698

Q58874870-C53D3CA3-1483-4AE1-9640-43FCA5035397

P921

Q58874870-24B154F1-A892-43AB-846D-0B1B6F2E35E4

Q58874870-9D9FBCF6-EEFE-4C50-A9B3-9CFFEBB2D5B9

Q58874870-ACA533B7-F2F5-4546-AA25-E854A9565EB9

P356

P1433

Arthritis and Rheumatism

P1476

Intravenous ibandronate inject ...... travenous administration study

@en

P2093

Cezary Strugala

http://www.w3.org/2001/XMLSchema#string

Claire Hughes

http://www.w3.org/2001/XMLSchema#string

Claus Christiansen

http://www.w3.org/2001/XMLSchema#string

Daiva Masanauskaite

http://www.w3.org/2001/XMLSchema#string

David M Reid

http://www.w3.org/2001/XMLSchema#string

Dieter Felsenberg

http://www.w3.org/2001/XMLSchema#string

Jacob A Stakkestad

http://www.w3.org/2001/XMLSchema#string

Jean-Yves Reginster

http://www.w3.org/2001/XMLSchema#string

Marc K Drezner

http://www.w3.org/2001/XMLSchema#string

Michael Bolognese

http://www.w3.org/2001/XMLSchema#string

P304

1838-1846

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.21918

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Civitelli

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16729277

http://www.w3.org/2001/XMLSchema#string

P921